Silence Therapeutics plc

Management Reports • Jan 27, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1726D

Silence Therapeutics PLC

27 January 2015

27 January 2015

Silence Therapeutics plc

Grant of share options

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the development and delivery of RNA therapeutics for the treatment of serious diseases, has awarded options over 153,000 ordinary shares to its recently appointed Head of Research and Development, Dr Lars Karlsson, in accordance with the terms of the Company's share option plan.

The options will vest after three years and have an exercise price of 205p, being the closing price on 7 January 2015, the day before Dr Karlsson joined the Company. They are also subject to a 400p price hurdle.

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Timothy Freeborn, Finance Director
Rozi Morris, Communications Manager
Canaccord Genuity Limited	+44 (0)20 7523 8350
Dr Julian Feneley/Cara Griffiths/Henry Fitzgerald-O'Connor

About Silence Therapeutics  (www.silence-therapeutics.com) 

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPKADNOBKDQDB